Durham, NC (September 28, 2021) – Scientists are reporting promising results in the early stages of a clinical trial designed to gauge the feasibility of a new type of treatment for people with acute kidney disease. Released in STEM CELLS Translational Medicine, the study shows how mesenchymal stromal cells (MSCs) delivered using a new ex vivo drug delivery system – SBI-101 – can keep MSCs viable longer and reprogram the peripheral immune response toward organ repair.
Acute kidney disease occurs when a kidney is suddenly unable to do its job of filtering blood and allows dangerous levels of waste to accumulate. The most severe cases require dialysis or a kidney transplant. Unfortunately, dialysis-dependent acute kidney injury has a mortality rate as high as 50 to 70 percent.